Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > my, my. Good thing that we are staying halted.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by losingmyshirton Sep 29, 2020 2:52pm
217 Views
Post# 31636303

my, my. Good thing that we are staying halted.

my, my. Good thing that we are staying halted.

Questions & Answers about Kalytera Therapeutics Projection

What is the Kalytera Therapeutics stock price / share price today?

The Kalytera Therapeutics stock price is 0.000100 USD today.

Will KALTF stock price drop / fall?

Yes. The Kalytera Therapeutics stock price may drop from 0.000100 USD to 0.000001 USD . The change will be -100.000%.

Will KALTF stock price grow / rise / go up?

No. See above.

Will KALTF stock price crash?

According to our analysis, this can happen.

Will Kalytera Therapeutics stock price hit 1 USD price in a year?

Not within a year. See above.

Will Kalytera Therapeutics stock price hit 5 USD price in a year?

Not within a year. See above.

Will Kalytera Therapeutics stock price hit 10 USD price in a year?

Not within a year. See above.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities